Acute decompensated heart failure: workup and management
Acute decompensated heart failure. Classify by congestion and perfusion (warm/cold, wet/dry), find the precipitant, decongest with IV loop diuretics, and keep guideline-directed medical therapy going where possible.
Working diagnosis
Adult · US guidelines
Draft · awaiting physician review
01Orient
What's new in the evidence
- DICTATE-AHF (2024): starting dapagliflozin early in the admission improved diuretic efficiency; start an SGLT2 inhibitor in hospital once stable
- PUSH-AHF (2023): natriuresis-guided diuretic titration increased sodium excretion; a spot urine sodium <50–70 mEq/L at 2 hours flags an inadequate response
- STRONG-HF (2022): rapid up-titration of GDMT before and within 6 weeks after discharge reduced death or HF readmission
- FINEARTS-HF (2024): finerenone reduced worsening HF events with LVEF ≥40%
- ADVOR (2022): acetazolamide added to loop diuretics improved decongestion
Differential diagnoses
- Precipitant: ACS, arrhythmia (AF), uncontrolled hypertension
- Precipitant: medication or diet non-adherence, NSAIDs, negative inotropes
- Precipitant: infection, anemia, thyroid disease
- Valve disease (acute MR, aortic stenosis)
- Mimics: COPD, pneumonia, PE, nephrotic syndrome, cirrhosis
02Assess
Risk scores and decision tools
- Hemodynamic profile: warm/cold and wet/dry
- Spot urine sodium 2 hours after loop diuretic (<50–70 mEq/L = escalate)
- GWTG-HF in-hospital mortality risk score
- NT-proBNP trajectory before discharge
Key history questions
- Dyspnea, orthopnea, PND, weight gain, edema
- Diuretic dose and adherence; salt and fluid intake
- Recent NSAIDs, steroids, non-dihydropyridine CCBs
- Chest pain, palpitations
- Known ejection fraction
Examination findings
- JVP, hepatojugular reflux
- Crackles, effusions
- Peripheral edema, ascites
- Cool peripheries, narrow pulse pressure, confusion (low output)
- S3, new murmurs
03Investigate
Initial investigations
- ECG
- Chest X-ray
- BNP or NT-proBNP, troponin
- BMP, magnesium, CBC, LFTs, TSH
- Point-of-care ultrasound (B-lines, IVC, effusion)
Advanced investigations
- Echocardiogram if none recent or a change is suspected
- Iron studies (ferritin, transferrin saturation)
- Ischemia evaluation for new HFrEF
04Treat
Immediate management
- Sit upright; oxygen if hypoxic
- CPAP/BiPAP for pulmonary edema with respiratory distress
- IV loop diuretic: 1-2.5 times the total daily oral furosemide dose given IV (40 mg IV if diuretic-naive)
- IV nitroglycerin for hypertensive pulmonary edema
First-line treatment
- Target net negative 1–2 L/day; check spot urine sodium about 2 hours after the dose and double the loop dose if response is poor
- Continue GDMT unless hypotensive, in shock or with severe AKI or hyperkalemia
- Start an SGLT2 inhibitor in hospital once hemodynamically stable (eGFR ≥20–25)
- Up-titrate GDMT rapidly around discharge (STRONG-HF approach)
- Treat the precipitant
Second-line treatment
- Sequential nephron blockade (metolazone or acetazolamide) for diuretic resistance
- Inotropes for cardiogenic shock with cardiology/ICU
- IV iron if iron deficient
Specialist referrals
- Cardiology for new HF, cardiogenic shock or advanced therapies
- Heart failure nurse or clinic before discharge
05Disposition
Admission criteria
- Hypoxia or respiratory distress
- Need for IV diuretics
- Hypotension, low output, ACS or arrhythmia
- Worsening renal function or electrolyte disturbance
Safe discharge criteria
- Euvolemic or near dry weight on oral diuretics for 24 h
- Stable renal function and electrolytes
- GDMT started or optimized
- Follow-up within 7 days
Follow-up timing
- Clinic visit or call within 7 days of discharge
- BMP within 1 week
Patient instructions
- Daily morning weights; call if up 1 kg (2 lb) in a day or 2 kg (5 lb) in a week
- Sodium under 2 g/day; avoid NSAIDs
Monitoring
- Daily weight and strict fluid balance
- Daily BMP and magnesium during IV diuresis
Clinical pearls and pitfalls
- HFrEF GDMT: ARNI/ACEi/ARB, evidence-based beta-blocker, MRA, SGLT2 inhibitor
- A small creatinine rise during effective decongestion is acceptable
RefGuidelines and landmark evidence
- GuidelineAHA/ACC/HFSA – Guideline for the Management of Heart Failure (2022)PubMed
- TrialDOSE: diuretic strategies in ADHF (2011)PubMed
- TrialADVOR: acetazolamide in ADHF (2022)PubMed
- TrialSTRONG-HF: rapid up-titration of GDMT after admission (2022)PubMed
- TrialDICTATE-AHF: early dapagliflozin in acute heart failure (2024)PubMed
- TrialPUSH-AHF: natriuresis-guided diuretic therapy (2023)PubMed
- TrialFINEARTS-HF: finerenone with LVEF ≥40% (2024)PubMed
For education only. Typical adult starting points; confirm doses against renal function, allergies, interactions and your institution's protocols. Not a substitute for clinical judgment or senior review.